Repression of engrailed 2 inhibits the proliferation and invasion of human bladder cancer in vitro and in vivo

Li,Yunfei; Liu,Haitao; Lai,Caiyong; Su,Zexuan; Heng,Baoli; Gao,Shuangquan

doi:10.3892/or.2015.3858

Repression of engrailed 2 inhibits the proliferation and invasion of human bladder cancer in vitro and in vivo

Authors:
- Yunfei Li
- Haitao Liu
- Caiyong Lai
- Zexuan Su
- Baoli Heng
- Shuangquan Gao
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital, Jinan University, Guangzhou, Guangdong 510630, P.R. China, Department of Obstetrics and Gynecology, Guangdong Women and Children's Hospital, Guangzhou, Guangdong 511400, P.R. China, Department of Pathology, Yuebei People's Hospital, Shaoguan, Guangdong 512026, P.R. China
Published online on: March 17, 2015 https://doi.org/10.3892/or.2015.3858
Pages: 2319-2330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Engrailed 2 (EN2) is a member of the homeobox gene family. Many studies suggest that overexpression of EN2 protein may be associated with tumor development, including bladder cancer (BC). However, to date, the mechanisms of how EN2 functions to promote BC progression remain elusive. The present study introduced RNAi to silence the expression of EN2 in BC cell lines. In vitro invasion and migration assays and in vivo experiments were carried out to examine the functions of EN2 in BC invasion and metastasis. The results of the present study indicated that EN2 was significantly expressed in BC cells. Ectopic expression of EN2 in normal urothelial cells significantly enhanced cellular proliferation and invasion, but inhibited cellular apoptosis. EN2 knockdown significantly promoted cell cycle arrest and apoptosis of BC cells with inhibition of proliferation and invasion in vitro as well as EN2 knockdown decreased the tumor growth of BC. The tumor growth was decreased by regulation of the cell cycle, apoptosis and epithelial-mesenchymal transition-related proteins, with inhibition of metastasis to the liver and lung in vivo. Furthermore, EN2 knockdown significantly decreased the levels of pAkt-473, pAkt-308 and phosphatidylinositol 3-kinase (PI3K), whereas EN2 knockdown increased the expression of PTEN in vitro. Taken together, EN2 may be a candidate oncogene in BC by activating the PI3K/Akt pathway and inhibiting PTEN, and may be a potential therapeutic target for the treatment of BC.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
2	Han S, Zhang S, Chen W and Li C: Analysis of the status and trends of bladder cancer incidence in China. Oncol Prog. 11:89–95. 2013.In Chinese.
3	Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
4	Gakis G, Witjes JA, Compérat E, Cowan NC, De Santis M, Lebret T, Ribal MJ and Sherif AM; European Association of Urology: EAU guidelines on primary urethral carcinoma. Eur Urol. 64:823–830. 2013. View Article : Google Scholar : PubMed/NCBI
5	Na Y and Guo Z: Practice of Urology. People’s Medical Press; Beijing: pp. 280–296. 2009, In Chinese.
6	Wu X: Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 5:713–725. 2005. View Article : Google Scholar : PubMed/NCBI
7	Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, Coen JJ, Skowronski RY, Paly JJ, McGovern FJ, et al: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol. 61:705–711. 2012. View Article : Google Scholar
8	Wedeen CJ and Weisblat DA: Segmental expression of an engrailed-class gene during early development and neurogenesis in an annelid. Development. 113:805–814. 1991.PubMed/NCBI
9	Wanninger A and Haszprunar G: The expression of an engrailed protein during embryonic shell formation of the tusk-shell, Antalis entails (Mollusca, Scaphopoda). Evol Dev. 3:312–231. 2001. View Article : Google Scholar : PubMed/NCBI
10	Fjose A, McGinnis WJ and Gehring WJ: Isolation of a homoeo box-containing gene from the engrailed region of Drosophila and the spatial distribution of its transcripts. Nature. 313:284–289. 1985. View Article : Google Scholar : PubMed/NCBI
11	Holland LZ, Kene M, Williams NA and Holland ND: Sequence and embryonic expression of the amphioxus engrailed gene (AmphiEn): the metameric pattern of transcription resembles that of its segment-polarity homolog in Drosophila. Development. 124:1723–1732. 1997.PubMed/NCBI
12	Joyner AL, Kornberg T, Coleman KG, Cox DR and Martin GR: Expression during embryogenesis of a mouse gene with sequence homology to the Drosophila engrailed gene. Cell. 43:29–37. 1985. View Article : Google Scholar : PubMed/NCBI
13	Hanks M, Wurst W, Anson-Cartwright L, Auerbach AB and Joyner AL: Rescue of the En-1 mutant phenotype by replacement of En-1 with En-2. Science. 269:679–682. 1995. View Article : Google Scholar : PubMed/NCBI
14	Hanks MC, Loomis CA, Harris E, Tong CX, Anson-Cartwright L, Auerbach A and Joyner A: Drosophila engrailed can substitute for mouse Engrailed1 function in mid-hindbrain, but not limb development. Development. 125:4521–4530. 1998.PubMed/NCBI
15	Simon HH, Saueressig H, Wurst W, Goulding MD and O’Leary DD: Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J Neurosci. 21:3126–3134. 2001.PubMed/NCBI
16	Alberi L, Sgado P and Simon HH: Engrailed genes are cell autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons. Development. 131:3229–3236. 2004. View Article : Google Scholar
17	Degenhardt K, Rentschler S, Fishman G and Sassoon DA: Cellular and cis-regulation of En-2 expression in the mandibular arch. Mech Dev. 111:125–136. 2002. View Article : Google Scholar : PubMed/NCBI
18	Martin NL, Saba-El-Leil MK, Sadekova S, Meloche S and Sauvageau G: EN2 is a candidate oncogene in human breast cancer. Oncogene. 24:6890–6901. 2005. View Article : Google Scholar : PubMed/NCBI
19	Bose SK, Bullard RS and Donald CD: Oncogenic role of engrailed-2 (en-2) in prostate cancer cell growth and survival. Transl Oncogenomics. 3:37–43. 2008.PubMed/NCBI
20	Morgan R, Boxall A, Bhatt A, et al: Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer. Clin Cancer Res. 17:1090–1098. 2011. View Article : Google Scholar : PubMed/NCBI
21	Pandha H, Sorensen KD, Orntoft TF, Langley S, Hoyer S, Borre M and Morgan R: Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 110:E287–E292. 2012. View Article : Google Scholar : PubMed/NCBI
22	McGrath SE, Michael A, Pandha H and Morgan R: Engrailed homeobox transcription factors as potential markers and targets in cancer. FEBS Lett. 587:549–554. 2013. View Article : Google Scholar : PubMed/NCBI
23	Morgan R, Bryan RT, Javed S, Launchbury F, Zeegers MP, Cheng KK, James ND, Wallace DM, Hurst CD, Ward DG, et al: Expression of Engrailed-2 (EN2) protein in bladder cancer and its potential utility as a urinary diagnostic biomarker. Eur J Cancer. 49:2214–2222. 2013. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Cantley LC: The phosphoinositide 3-kinase pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
26	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: rationale and premise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
27	Shaw RJ and Cantley LC: Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 441:424–430. 2006. View Article : Google Scholar : PubMed/NCBI
28	Peter M and Herskowitz I: Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 79:181–184. 1994. View Article : Google Scholar : PubMed/NCBI
29	Al Hussain TO and Akhtar M: Molecular basis of urinary bladder cancer. Adv Anat Pathol. 20:53–60. 2013. View Article : Google Scholar
30	Cordes I, Kluth M, Zygis D, Rink M, Chun F, Eichelberg C, Dahlem R, Fisch M, Höppner W, Wagner W, et al: PTEN deletions are related to disease progression and unfavourable prognosis in early bladder cancer. Histopathology. 63:670–677. 2013.PubMed/NCBI
31	Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 26:1324–1337. 2007. View Article : Google Scholar : PubMed/NCBI
32	Haupt S, Berger M, Goldberg Z and Haupt Y: Apoptosis - the p53 network. J Cell Sci. 116:4077–4085. 2003. View Article : Google Scholar : PubMed/NCBI
33	Maehama T and Dixon JE: The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
34	Nicholson KM and Anderson NG: The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal. 14:381–395. 2002. View Article : Google Scholar : PubMed/NCBI
35	Diehl JA: Cycling to cancer with cyclin D1. Cancer Biol Ther. 1:226–231. 2002. View Article : Google Scholar : PubMed/NCBI
36	Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res. 33:5235–5242. 2013.PubMed/NCBI
37	Fang Y, Cao Z, Hou Q, Ma C, Yao C, Li J, Wu XR and Huang C: Cyclin d1 downregulation contributes to anticancer effect of isorhapontigenin on human bladder cancer cells. Mol Cancer Ther. 12:1492–1503. 2013. View Article : Google Scholar : PubMed/NCBI
38	Gee JR, Burmeister CB, Havighurst TC and Kim K: Cyclinmediated G1 arrest by celecoxib differs in low-versus high-grade bladder cancer. Anticancer Res. 29:3769–3775. 2009.PubMed/NCBI
39	Appelmann L, Liersch R, Kessler T, Mesters RM and Berdel WE: Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy. Recent Results Cancer Res. 180:51–81. 2010. View Article : Google Scholar
40	Moh MC and Shen S: The roles of cell adhesion molecules in tumor suppression and cell migration: a new paradox. Cell Adh Migr. 3:334–336. 2009. View Article : Google Scholar : PubMed/NCBI
41	Rodriguez Faba O, Palou-Redorta J, Fernández-Gómez JM, Algaba F, Eiró N, Villavicencio H and Vizoso FJ: Matrix metalloproteinases and bladder cancer: what is new? ISRN Urol. 2012:5815392012.PubMed/NCBI
42	Yuan TL and Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
43	Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
44	López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardón A, Serra C and Real FX: PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 66:7401–7404. 2006. View Article : Google Scholar : PubMed/NCBI
45	Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P and Knowles MA: Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res. 15:6008–6017. 2009. View Article : Google Scholar : PubMed/NCBI
46	Knowles MA, Platt FM, Ross RL and Hurst CD: Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev. 28:305–316. 2009. View Article : Google Scholar : PubMed/NCBI
47	Askham JM, Platt F, Chambers PA, Snowden H, Taylor CF and Knowles MA: AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene. 29:150–155. 2010. View Article : Google Scholar
48	Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M and de la Taille A: PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer. 134:1776–1784. 2014. View Article : Google Scholar
49	Cully M, You H, Levine AJ and Mak TW: Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 6:184–192. 2006. View Article : Google Scholar : PubMed/NCBI
50	Nedelec S, Foucher I, Brunet I, Bouillot C, Prochiantz A and Trembleau A: Emx2 homeodomain transcription factor interacts with eukaryotic translation initiation factor 4E (eIF4E) in the axons of olfactory sensory neurons. Proc Natl Acad Sci USA. 101:10815–10820. 2004. View Article : Google Scholar : PubMed/NCBI
51	Zhou J, Qin L, Tien JC, Gao L, Chen X, Wang F, Hsieh JT and Xu J: Nkx3.1 functions as para-transcription factor to regulate gene expression and cell proliferation in non-cell autonomous manner. J Biol Chem. 287:17248–17256. 2012. View Article : Google Scholar : PubMed/NCBI
52	Prin F, Serpente P, Itasaki N and Gould AP: Hox proteins drive cell segregation and non-autonomous apical remodelling during hindbrain segmentation. Development. 141:1492–1502. 2014. View Article : Google Scholar : PubMed/NCBI